Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates with Phylogenetic Distance from HPV Vaccine Types 16 and 18

Johannes A. Bogaards, Pascal van der Weele, Petra J. Woestenberg, Birgit H. B. van Benthem, Audrey J. King

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and-18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31,-33,-35,-45,-52, and possibly-58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or-18.
Original languageEnglish
Pages (from-to)1141-1146
JournalJournal of Infectious Diseases
Volume220
Issue number7
DOIs
Publication statusPublished - 30 Aug 2019
Externally publishedYes

Cite this

Bogaards, Johannes A. ; van der Weele, Pascal ; Woestenberg, Petra J. ; van Benthem, Birgit H. B. ; King, Audrey J. / Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates with Phylogenetic Distance from HPV Vaccine Types 16 and 18. In: Journal of Infectious Diseases. 2019 ; Vol. 220, No. 7. pp. 1141-1146.
@article{11ef7b15361846a9aa904b339bba5729,
title = "Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates with Phylogenetic Distance from HPV Vaccine Types 16 and 18",
abstract = "To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and-18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31,-33,-35,-45,-52, and possibly-58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or-18.",
author = "Bogaards, {Johannes A.} and {van der Weele}, Pascal and Woestenberg, {Petra J.} and {van Benthem}, {Birgit H. B.} and King, {Audrey J.}",
year = "2019",
month = "8",
day = "30",
doi = "10.1093/infdis/jiz280",
language = "English",
volume = "220",
pages = "1141--1146",
journal = "Journal of Infectious Diseases",
issn = "0022-1899",
publisher = "Oxford University Press",
number = "7",

}

Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates with Phylogenetic Distance from HPV Vaccine Types 16 and 18. / Bogaards, Johannes A.; van der Weele, Pascal; Woestenberg, Petra J.; van Benthem, Birgit H. B.; King, Audrey J.

In: Journal of Infectious Diseases, Vol. 220, No. 7, 30.08.2019, p. 1141-1146.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates with Phylogenetic Distance from HPV Vaccine Types 16 and 18

AU - Bogaards, Johannes A.

AU - van der Weele, Pascal

AU - Woestenberg, Petra J.

AU - van Benthem, Birgit H. B.

AU - King, Audrey J.

PY - 2019/8/30

Y1 - 2019/8/30

N2 - To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and-18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31,-33,-35,-45,-52, and possibly-58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or-18.

AB - To substantiate cross-protection reported across AS04-adjuvanted bivalent human papillomavirus (HPV) vaccine (2vHPV) studies, we reevaluated vaccine effectiveness against type-specific HPV positivity as a function of phylogenetic distance to vaccine target types HPV-16 and-18. We provide evidence of sustained cross-protection up to 8 years postvaccination in a high-risk population in the Netherlands. Moreover, our findings suggest that genomic distance better explains cross-protection than distance measures based on capsid antigens only. Taken together, 2vHPV is predicted to provide partial cross-protection against HPV-31,-33,-35,-45,-52, and possibly-58, that is, acknowledged oncogenic types with close phylogenetic relationships to HPV-16 or-18.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85072056384&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/31165164

U2 - 10.1093/infdis/jiz280

DO - 10.1093/infdis/jiz280

M3 - Article

VL - 220

SP - 1141

EP - 1146

JO - Journal of Infectious Diseases

JF - Journal of Infectious Diseases

SN - 0022-1899

IS - 7

ER -